JP2004244389A - Dietary supplement - Google Patents

Dietary supplement Download PDF

Info

Publication number
JP2004244389A
JP2004244389A JP2003037382A JP2003037382A JP2004244389A JP 2004244389 A JP2004244389 A JP 2004244389A JP 2003037382 A JP2003037382 A JP 2003037382A JP 2003037382 A JP2003037382 A JP 2003037382A JP 2004244389 A JP2004244389 A JP 2004244389A
Authority
JP
Japan
Prior art keywords
extract
white peach
agent
constipation
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003037382A
Other languages
Japanese (ja)
Inventor
Tatsuo Takahashi
龍男 高橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RYUEI SOKEN KK
Original Assignee
RYUEI SOKEN KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RYUEI SOKEN KK filed Critical RYUEI SOKEN KK
Priority to JP2003037382A priority Critical patent/JP2004244389A/en
Publication of JP2004244389A publication Critical patent/JP2004244389A/en
Pending legal-status Critical Current

Links

Images

Abstract

<P>PROBLEM TO BE SOLVED: To provide a dietary supplement having improved anti-obesity action and anti-constipation action of Hakutoka (blossom of white peach flower) and Chinpi (dried orange peel). <P>SOLUTION: The dietary supplement, the anti-obesity agent or the anti-constipation agent contains an extract of Hakutoka; an extract of Chinpi and an extract of Kijitsu (unripe fruit of Citrus aurantium); and an extract of Yotei (root of Rumex japonicus) at ratios of from 2:1:2 to 1:1:2. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
本発明は栄養補助食品に関するものであり、特に抗肥満作用、抗便秘作用を呈する栄養補助食品に関する。
【0002】
【従来の技術】
白桃花は、バラ科の植物である“もも”(Prunuspersica(L.)Betscg)の花であり、Kaempterol, Trifolim, Ringenin等のフラボノイドを含む。白桃花には、利尿作用、瀉下作用、新陳代謝亢進作用、血流改善作用などがあり、便秘、むくみ、肥満、婦人科系愁訴の抑制に応用することができる。このうち、新陳代謝更新作用が肥満の抑制に大きく寄与するものと考えられる。
【0003】
一方、陳皮、枳殻、枳実、青皮、橘紅等の柑橘類の皮には整腸作用、健胃作用が認められる。
【0004】
また、タデ科の植物である羊蹄(ギシギシ)には抗菌効果が認められる。
【0005】
【発明が解決しようとする課題】
上述の通り、白桃花は便秘、むくみ、肥満等を改善する作用を有するが、その瀉下作用は非常に強力であり、そのまま服用すると腹痛を伴う激しい下痢を引き起こしてしまうことが多い。下痢が続くとカリウム等の必須ミネラルの吸収不足から水分代謝異常や、心不全といった重篤な副作用が発現するおそれもあるため、下痢の症状が発現した場合は白桃花の服用は中止せざるを得ない。すなわち、白桃花を単独で服用した場合は、症状を改善する前に患者が服薬に耐えられなくなってしまうと言う問題がある。
【0006】
本願人の特願2001−241378に記載されている発明は、この問題を解決するためのものであり、当該明細書に記載されているとおり、陳皮を白桃花と共に服用することにより、白桃花の激しい通便作用を緩和させることができることが本発明者によって確認された。
【0007】
【発明が解決しようとする課題】
本発明者は、白桃花の過剰な消化管の運動を抑制し、かつ肥満抑制作用を温存させるべく、整腸作用を有する様々な生薬を白桃花に添加して実験を行った結果、陳皮、枳殻(枳実)等の柑橘類の皮がその目的を達成できることを発見した。
【0008】
本願第1発明(請求項1〜6に記載の発明)は、これら柑橘類の皮のエキスを白桃花エキスに加えて、白桃花の瀉下作用を抑制した栄養補助食品、抗肥満剤、抗便秘剤を提供することを目的とする。このうち、白桃花と陳皮の作用については、本願人の特願2001−241378に詳しく記載されている。
【0009】
本発明者は更に研究を続けた結果、白桃花に陳皮等を加えた栄養補助食品(抗肥満剤、抗便秘剤)を服用した場合、時に、軟便になったり、また、便通の回数が増えて1日に2〜3回も排便しなければならなくなったり、あるいは腸管にガスが溜まって、いわゆる“渋り腹”となることがあることを確認した。
【0010】
このような現象は、通常の便秘改善薬を服用した場合にも発現することがある。その原因は、腸管の激しい蠕動運動により食物が未消化のまま大腸に運ばれるため、大腸内の細菌が栄養分に富んだ未消化の便を急速に発酵させるためであると言われている。常習の便秘であれば、腸内細菌のバランスが有害菌に傾いているので、腐敗を伴うこともある。
【0011】
本発明者は、羊蹄(ギシギシ)に腸内細菌のバランスを崩すことなく、異常発酵を防ぐ作用があることを発見し、白桃花と、陳皮等の柑橘類の皮との混合物に更に羊蹄(ギシギシ)を加えることによって、上記問題を解決できることを発見した。
【0012】
本願第2発明(請求項7〜9に記載の発明)は、異常発酵のない普通便を排泄させ、便通の回数も1日1回程度で収まり、大腸内の膨満感を発現しない、理想的な栄養補助食品、抗便秘剤、抗肥満剤を提供することを目的とする。
【0013】
【課題を解決するための手段】
【0014】
本願第1発明の栄養補助食品、抗肥満剤、抗便秘剤は、白桃花エキスと;枳実エキスとを3:1〜2:5の割合、より好ましくは2:1〜1:2の割合で含むことを特徴とする。
【0015】
また、本願第1発明の栄養補助食品、抗肥満剤、抗便秘剤は、白桃花エキスと;枳実エキスと陳皮エキスの混合物を3:1〜2:5の割合、より好ましくは2:1〜1:2の割合で含むことを特徴とする。
【0016】
白桃花の成分比が上記の割合(白桃花エキス:柑橘類の皮エキス 3:1〜2:5)以下では、新陳代謝亢進効果を示さず、上記の割合以上では過剰に作用して下痢や、嘔吐等の好ましくない症状が現れてしまう。また、陳皮等の柑橘類の皮エキスの成分比が上記の割合以下では、白桃花の作用が過剰になることを抑制できず、上記の割合以上では、白桃花の作用を過剰に抑制することになる。なお、白桃花エキスと、陳皮等の柑橘類の皮エキスの成分比が2:1〜1:2である場合に、最も顕著な効果が得られる。柑橘類の皮エキスは、一種でも、複数種を混合したものでもよい。
【0017】
本願第2発明は、白桃花の激しい瀉下作用を抑え、かつ普通便を排泄させ、排便回数を適度に抑え、更に大腸内の膨満感が生じない栄養補助食品、抗肥満剤、抗便秘剤を提供することを目的としており、この目的を達するべく、本願第2発明にかかる栄養補助食品、抗肥満剤、抗便秘剤は、白桃花エキスと;陳皮エキスおよび/または枳実エキスと;羊蹄(ギシギシ)エキスとを2:1:2〜1:1:2の割合で含むことを特徴とする。
【0018】
白桃花エキスと、陳皮等および/または枳実エキスと、羊蹄(ギシギシ)エキスの成分比が、上記の割合を逸脱すると、軟便になったり、便通の回数が増える、下腹部の膨満感を覚えるといった問題は解決しない。また、白桃花の持つ新陳代謝亢進作用等を適度に発現させ、かつ瀉下作用を抑えることが困難となる。
【0019】
なお、本明細書において、エキスとは、液状、粉末状、固形の抽出物、原体の乾燥粉末等を含む概念である。
【0020】
【実施例】
本発明者は、本発明の効果を実証すべく、以下の通りの臨床実験を行った。
【0021】
上述したとおり、白桃花には、利尿、通便、新陳代謝亢進、通経、自律神経調整等の作用があるため、古くから、肥満抑制や婦人科疾患から生じる各種不定愁訴の改善に用いられてきた。しかし、瀉下ともいえる通便作用があるため、服用した者は体調を崩し、肥満抑制効果や婦人科疾患の改善が見られる前に服用を中止せざるを得ない者が多い。本願人の特願2001−241378に記載したとおり、白桃花に更に陳皮を加えると、このデメリットが緩和されることが解っているが、この場合でも、大腸内にガスが溜まり、腹部膨満感を訴える者が多数いる。
【0022】
この原因は、大腸内の細菌による異常発酵であると考えられ、大腸内細菌のバランスを崩さずに異常発酵を抑える作用のある羊蹄(ギシギシ)を更に加えた生薬を投薬して、臨床テストを行った。
【0023】
臨床テスト概要
(1)対象者
24〜63歳までの35名の常習便秘患者に白桃花と陳皮の混合末を投与し、これらの患者のうち。便秘は解消したが、下腹部の膨満感(大腸内のガス充満)を訴える者11名を対象に臨床テストを行った。この11名の患者は、26歳から63歳までの女性で、全員肥満体であり、月経痛、月経不順等を訴える者が含まれている。
【0024】
(2)使用薬剤
1カプセル中に白桃花末150mg、陳皮末60mgを含有する試験剤Aと、1カプセル中に白桃花末150mg、陳皮末60mg、羊蹄(ギシギシ)末150mgを含有する試験剤Bを用意した。
【0025】
(3)投与方法と投与期間
各被験者に5日間に渡って、1日1回試験剤Aを夕食後に9カプセル服用させた。その後、更に5日間に渡って、1日1回試験剤Bを夕食後に9カプセル服用させた。また、状況に応じて、更に試験剤Bを3ヶ月間投与した。
【0026】
(4)併用薬剤
被験者が今まで服用していた薬剤は、そのまま継続して服用してもらい、新たに薬剤を追加服用することは禁じた。
【0027】
(5)その他
食生活や運動等は今までどおりとしてもらった。
【0028】
(6)試験概要
各被験者に、試験剤Aを5日間投与し、その間の排便の有無、大便の状態、下腹部膨満感の有無を調べた。5日目に、pH試験紙を用いて大便のpHを測定した。その後、試験剤をBに変えて更に5日間投与し、その間の排便の有無、対便の状態、下腹部膨満感の有無を調べた。また、同様に、pH試験紙を用いて大便のpHを測定した。
【0029】
更に、試験剤Bに試験剤Aと同等の便秘改善作用があり、かつ下腹部膨満感を抑制する作用があると判断された患者については、試験剤Bの投与期間を3ヶ月延長して、各被験者の体重や愁訴の最終的な変化を調べた。
【0030】
(7)判定方法
試験剤Aには、すでに行った動物実験や臨床テストで(特願2001−241378参照)便秘改善効果があることが判明している。従って、試験剤Aを5日間投与したときの排便の有無や大便の状態と、試験剤Bを5日間投与したときの排便の有無や大便の状態とを比較して、試験剤Bに試験剤Aと同等の排便作用がある場合には、試験剤Bには便秘改善効果があると判定した。
【0031】
ただし、試験剤Aには、大腸内のガス充満による下腹部膨満感が現れるので、この試験剤Aによる下腹部膨満感が、試験剤Bの投与によってどのように変化したかを調べた。この変化は、下腹部膨満感を全く自覚しなくなった場合を「著効」とし、下腹部膨満感が軽減した場合を「有効」とし、変わらず下腹部膨満感を感じる場合を「無効」とし、逆に下腹部膨満感がひどく感じられる場合を「悪化」としてて判定した。
【0032】
大腸内ガスの大量発生は、大腸内細菌による異常発酵や、腐敗によるものであり、この発酵、腐敗の結果、大便が酸性またはアルカリ性に傾くことになる。従って、試験剤Aを5日間投与した後の大便のpH値(第1のpH値)と、その後5日間試験剤Bを投与した後の大便のpH値(第2のpH値)を比較した。
【0033】
ここで、健常者の大便はpH値が中性を示すことが判明しているので、第2のpH値が、第1のpH値に比して中性に近づいている場合を「有効」とし、逆に第2のpH値が第1のpH値に比較して中性から遠ざかっている場合を「悪化」と、pH値が変化しなかった場合を「無効」とした。つまり、このpH値の変化は、下腹部の膨満感の改善度を数値で表すものと言える。
【0034】
更に、試験剤Bに試験剤Aと同等の便秘改善作用があり、かつ、下腹部膨満感を抑制する作用があると判断された患者については、更に試験剤Bの投与期間を90日間に延長して、体重の変化や、各被験者の愁訴が最終的にどのようになったかを調べた。
【0035】
これは、たとえ白桃花に陳皮あるいは枳実や、羊蹄(ギシギシ)を加えて、白桃花の瀉下作用を緩和させ、かつ下腹部膨満感を抑制することができたとしても、この試験剤自体に婦人科系愁訴の改善作用が見られないのでは、本発明の栄養補助剤(抗肥満剤、抗便秘剤)を投与する意味がなくなるため、この改善効果を確認するべく行ったものである。
【0036】
この調査は、問診票を用意して、試験剤服用前の症状を記入してもらっておき、試験時Bの服用開始90日後に、各症状がどのように変化したかを再度記入してもらった。ここで、各症状が、大変良くなった場合を「著効」とし、良くなったを「有効」と、変わらない場合を「無効」と、逆に悪くなった場合を「悪化」とした。
【0037】
更に、肥満の改善に関して、試験剤の投与前と投与後の体重を測定して、その変化により判定した。すなわち、測定誤差を考慮して、4%以上の体重の減少を「有効」と、4%未満の減少から4%未満の増加を「無効」とし、4%異常の増加を「悪化」とした。なお、小数点以下は、四捨五入とした。
【0038】
臨床テスト結果
図1は、試験剤Aの便秘改善作用を示す表であり、図2は試験剤Bの便秘改善作用を示す表である。これらの表から、試験剤Bは、試験剤Aと同等の便秘改善作用があることがわかる。ここで、下腹部の膨満感は、試験剤Bの5日間の投与によって、被験者全員が全く感じなくなっている。また、試験剤Bを5日間投与した後の大便のpH値は、試験剤Aを5日間投与した後のpH値に比較すると、全員が中性に近づいている。
【0039】
図3は、上記臨床テストの総合結果を示す表である。すなわち、便秘の改善作用は、試験剤A、B共に同じように見られ、試験剤Bには、更に下腹部の膨満感を生じさせない作用が見られる。すなわち、試験剤Bは理想的な抗便秘剤であることが判明した。
【0040】
図4は、試験剤Bを引き続いて90日間使用した場合の、各愁訴の改善結果を示す表である。図4に示すとおり、各愁訴について、顕著な改善結果が見られた。すなわち、便秘はもちろんのこと、生理不順や、生理痛、腰痛、むくみについては90〜100%と言う高い改善率が見られた。
【0041】
図5は、同じく、試験剤Bを引き続いて90日間使用した場合の、各被験者の体重の変化を示す表である。図5に示すように、1例を除いて、ほとんどの被験者について体重の減少が顕著に見られた。中には、試験剤Bの90日間の服用で6〜9Kgの体重の減少が見られた者もいた。
【0042】
投与量
1日あたりの、各生薬の投与量は、原料換算で、白桃花1〜3gに相当するエキス、陳皮0.5〜3gに相当するエキス、羊蹄(ギシギシ)1〜6gに相当するエキスが適量と考えられる。陳皮エキスは、枳実(枳殻)エキス、あるいは陳皮エキスと、枳実(枳殻)エキスの混合物で代用することができる。
【0043】
また、白桃花エキスと;枳実(枳殻)エキス、または陳皮エキスと枳実(枳殻)エキスの混合物を投与する場合(本願第1発明)は、1日あたり、原料換算で、白桃花が1g〜3gに相当するエキス、枳実(枳殻)、あるいは陳皮と枳実の混合物0.5g〜3gに相当するエキスが適量と考えられる。
【0044】
白桃花エキス、陳皮エキス、枳実(枳殻)エキス、羊蹄(ギシギシ)のエキスは、通常の熱水抽出法を用いて製造したものを用いる。
【0045】
【発明の効果】
以上述べたとおり、本発明によれば、白桃花エキスと陳皮および/または枳実(枳殻)エキスの混合物に更に羊蹄(ギシギシ)を添加することによって、白桃花の激しい瀉下作用等を抑えて、白桃花の持つ新陳代謝亢進作用、血流改善作用による抗肥満効果を有効に利用し、更に下腹部の膨満感を抑えた栄養補助食品、抗肥満剤、あるいは抗便秘剤を提供することができる。
【図面の簡単な説明】
【図1】図1は、従来の白桃花エキスと陳皮エキスの混合物の有用性を示す表である。
【図2】図2は、本発明の、白桃花エキスと陳皮エキスの混合物に更に羊蹄(ギシギシ)を加えた抗便秘剤の有用性を示す表である。
【図3】図3は、本発明の、白桃花エキスと陳皮エキスの混合物に更に羊蹄(ギシギシ)を加えた栄養補助食品の有用性を示す表である。
【図4】図4は、本発明の白桃花エキスと陳皮エキスの混合物に更に羊蹄(ギシギシ)を加えた栄養補助食品の婦人科系愁訴に対する有用性を示す表である。
【図5】図5は、本発明の白桃花エキスと陳皮エキスの混合物に更に羊蹄(ギシギシ)を加えた栄養補助食品の抗肥満作用を示す表である。
[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a dietary supplement, and more particularly to a dietary supplement having an anti-obesity effect and an anti-constipation effect.
[0002]
[Prior art]
White peach blossoms are flowers of "peach" (Prunuspersica (L.) Betscg), a plant of the family Rosaceae, and include flavonoids such as Kaempterol, Trifolim, Ringenin and the like. White peach blossom has a diuretic effect, a purgative effect, a metabolism enhancing effect, a blood flow improving effect, and the like, and can be applied to control constipation, swelling, obesity, and gynecological complaints. Among them, the metabolic renewal effect is considered to greatly contribute to the suppression of obesity.
[0003]
On the other hand, the skin of citrus fruits such as rind, citrus, citrus, green skin, and red citrus have an intestinal regulating action and a stomachic effect.
[0004]
In addition, an antibacterial effect is recognized on Yotei (Rumex japonicus), a plant belonging to the Polygonaceae family.
[0005]
[Problems to be solved by the invention]
As described above, white peach blossom has an effect of improving constipation, swelling, obesity, etc., but its purgative effect is very powerful, and if taken as it is, it often causes severe diarrhea with abdominal pain. If diarrhea continues, serious side effects such as abnormal water metabolism and heart failure may occur due to insufficient absorption of essential minerals such as potassium, so if diarrhea occurs, it is necessary to stop taking white peach blossom Absent. In other words, there is a problem in that if white peach blossom is taken alone, the patient will not be able to tolerate the medication before the symptoms are improved.
[0006]
The invention described in Japanese Patent Application No. 2001-241378 of the present applicant is intended to solve this problem. As described in the specification, by taking the skin with white peach blossom, the invention of white peach blossom can be achieved. It has been confirmed by the present inventor that a severe defecation effect can be reduced.
[0007]
[Problems to be solved by the invention]
The present inventor, by suppressing the excessive gastrointestinal motility of white peach blossoms, and preserving the obesity suppression effect, as a result of conducting experiments by adding various crude drugs having an intestinal action to white peach blossoms, It has been discovered that citrus peels such as citrus can achieve their purpose.
[0008]
The first invention of the present application (the invention according to claims 1 to 6) is a dietary supplement, an anti-obesity agent, and an anti-constipation agent in which the citrus peel extract is added to the white peach flower extract to suppress the laxative effect of the white peach flower. The purpose is to provide. Of these, the effects of white peach blossoms and Chen skin are described in detail in Japanese Patent Application No. 2001-241378 of the present applicant.
[0009]
As a result of further research, the present inventor has found that when taking a dietary supplement (anti-obesity agent, anti-constipation agent) in which white peach blossoms are added to skin and the like, the stool sometimes loosens and the frequency of bowel movements increases. It was confirmed that the patient had to defecate two or three times a day, or that gas accumulated in the intestinal tract, resulting in a so-called "belly belly".
[0010]
Such a phenomenon may occur even when a usual constipation improving drug is taken. It is said that the cause is that food is transported undigested to the large intestine due to intense peristalsis of the intestine, and bacteria in the large intestine rapidly ferment undigested stool rich in nutrients. Habitual constipation can be spoiled because the balance of intestinal bacteria tends to harmful bacteria.
[0011]
The present inventor has found that sheep and hoof (Rigis fuscata) has an effect of preventing abnormal fermentation without disturbing the balance of intestinal bacteria, and the mixture of white peach blossoms and citrus peels such as cinnamon is further added to the mixture of sheep and hooves. ) Can solve the above problem.
[0012]
The second invention of the present application (the invention according to claims 7 to 9) is an ideal, which excretes ordinary stool without abnormal fermentation, and the stool frequency is reduced to about once a day, and does not cause bloating in the large intestine. It is an object of the present invention to provide nutritional supplements, anti-constipation agents, and anti-obesity agents.
[0013]
[Means for Solving the Problems]
[0014]
The dietary supplement, anti-obesity agent and anti-constipation agent of the first invention of the present application are white peach extract and kikomi extract in a ratio of 3: 1-2: 5, more preferably in a ratio of 2: 1-1: 2. It is characterized by including.
[0015]
Further, the dietary supplement, anti-obesity agent and anti-constipation agent of the first invention of the present application are a mixture of white peach extract and kikomi extract and skin extract in a ratio of 3: 1-2: 5, more preferably 2: 1-1. It is characterized in that it is contained at a ratio of 1: 2.
[0016]
When the composition ratio of white peach blossoms is less than the above ratio (white peach blossom extract: citrus peel extract 3: 1 to 2: 5), no metabolism-enhancing effect is exhibited, and when it is higher than the above ratio, it excessively acts to cause diarrhea and vomiting. Undesirable symptoms such as appear. In addition, if the component ratio of the citrus peel extract such as Chen Peel is less than the above ratio, the effect of the white peach blossom cannot be suppressed from becoming excessive, and if the component ratio is more than the above ratio, the action of the white peach blossom is excessively suppressed. Become. In addition, the most remarkable effect is obtained when the component ratio of the white peach extract and the citrus peel extract such as cinnamon is 2: 1 to 1: 2. The citrus peel extract may be one kind or a mixture of plural kinds.
[0017]
The second invention of the present application is to provide a dietary supplement, an anti-obesity agent, and an anti-constipation agent that suppresses the vigorous purgative action of white peach blossoms, excretes ordinary stool, moderately reduces the number of defecations, and does not cause bloating in the large intestine. To achieve this purpose, the dietary supplement, the anti-obesity agent and the anti-constipation agent according to the second invention of the present application include a white peach flower extract; a skin extract and / or a citrus extract; ) Extract at a ratio of 2: 1: 2 to 1: 1: 2.
[0018]
If the composition ratio of white peach blossom extract, cinnamon extract and / or citrus extract, and yotei (Rigix japonicus) extract deviates from the above ratio, loose stools, increased number of bowel movements, and a feeling of fullness in the lower abdomen can be obtained. The problem is not solved. In addition, it is difficult to adequately express the metabolism-enhancing action of the white peach blossom and to suppress the scavenging action.
[0019]
In addition, in this specification, an extract is a concept containing liquid, powdery, solid extract, original dry powder, and the like.
[0020]
【Example】
The present inventors conducted the following clinical experiments in order to demonstrate the effects of the present invention.
[0021]
As described above, white peach blossoms have effects such as diuresis, defecation, hypermetabolism, menstruation, and autonomic nervous regulation, and have long been used for suppressing obesity and improving various indefinite complaints resulting from gynecological diseases. Was. However, because of the defecation effect which can be said to be purgation, there are many people who have to take the drug before taking the sickness and obesity suppressing effect or improvement of gynecological diseases. As described in Japanese Patent Application No. 2001-241378 of the present applicant, it has been found that the addition of skin to white peach blossoms alleviates this disadvantage, but even in this case, gas accumulates in the large intestine, causing abdominal bloating. There are many who appeal.
[0022]
The cause is considered to be abnormal fermentation by bacteria in the large intestine, and a clinical test was conducted by administering a crude drug to which a sheep-hoof (Rigix japonicus), which has the effect of suppressing abnormal fermentation without disturbing the balance of colon bacteria, was added. went.
[0023]
Outline of clinical test (1) Subjects A mixture of white peach blossoms and chin skin was administered to 35 addictive constipation patients aged 24 to 63 years. Although constipation was resolved, a clinical test was conducted on 11 subjects who complained of bloating in the lower abdomen (filling of gas in the large intestine). The 11 patients were women aged 26 to 63, all obese, including those complaining of menstrual pain and irregular menstruation.
[0024]
(2) Test agent A containing 150 mg of white peach blossom powder and 60 mg of cinnamon powder in one capsule, and test agent B containing 150 mg of white peach blossom powder, 60 mg of cinnamon powder and 150 mg of daisies powder in one capsule Was prepared.
[0025]
(3) Administration method and administration period Each subject was allowed to take 9 capsules of test agent A once a day after dinner for 5 days. Thereafter, 9 capsules of test agent B were taken once a day after dinner for another 5 days. In addition, test agent B was further administered for 3 months depending on the situation.
[0026]
(4) Concomitant medications The subjects had been taking the medications that had been taken so far, and were prohibited from taking additional new medications.
[0027]
(5) Other dietary habits, exercises, etc. were received as before.
[0028]
(6) Test Overview Each test subject was administered test agent A for 5 days, and the presence or absence of bowel movements, the state of stool, and the presence of bloating in the lower abdomen during that period were examined. On the fifth day, the pH of the stool was measured using pH test paper. Thereafter, the test agent was changed to B and administered for another 5 days, and the presence or absence of defecation, the state of stool, and the presence or absence of lower abdominal swelling during that period were examined. Similarly, stool pH was measured using pH test paper.
[0029]
Furthermore, for patients determined that Test Agent B has the same constipation-improving effect as Test Agent A and has an effect of suppressing lower abdominal distension, the administration period of Test Agent B is extended by three months, The final changes in body weight and complaints of each subject were examined.
[0030]
(7) Judgment Method It has been found that Test Agent A has an effect of improving constipation in animal tests and clinical tests already performed (see Japanese Patent Application No. 2001-241378). Therefore, the presence or absence of stool and the state of stool when the test agent A was administered for 5 days were compared with the presence or absence of stool and the state of stool when the test agent B was administered for 5 days. When the defecation effect was equivalent to that of A, it was determined that the test agent B had a constipation improving effect.
[0031]
However, since Test Agent A exhibited a feeling of lower abdominal distension due to gas filling in the large intestine, it was examined how the lower abdominal distension caused by Test Agent A was changed by administration of Test Agent B. This change is defined as `` significant effect '' when the lower abdominal bloating is completely unrecognized, `` effective '' when the lower abdominal bloating is reduced, and `` ineffective '' when the lower abdominal bloating is still felt. Conversely, a case where the lower abdominal distension was severely felt was determined as “deterioration”.
[0032]
Mass production of gas in the large intestine is caused by abnormal fermentation or decay by bacteria in the large intestine, and as a result of this fermentation and decay, stool tends to be acidic or alkaline. Therefore, the pH value of the stool (first pH value) after administration of test agent A for 5 days was compared with the pH value of stool (second pH value) after administration of test agent B for 5 days. .
[0033]
Here, since it is known that the stool of a healthy person has a neutral pH value, the case where the second pH value is closer to neutral than the first pH value is “effective”. Conversely, the case where the second pH value was far from neutral compared to the first pH value was “deteriorated”, and the case where the pH value did not change was “invalid”. In other words, it can be said that this change in the pH value expresses the degree of improvement of the feeling of fullness of the lower abdomen by numerical values.
[0034]
Furthermore, for patients determined that Test Agent B has the same constipation-improving effect as Test Agent A and also has an effect of suppressing lower abdominal distension, the administration period of Test Agent B is further extended to 90 days. Then, changes in weight and the final complaints of each subject were examined.
[0035]
This is because even if it was possible to reduce the laxative effect of white peach blossoms and to suppress the lower abdominal distension by adding white skin peaches, cinnamon or kikumi or yotei, the test agent itself could be used by women. If there is no effect of improving the family complaints, it is meaningless to administer the nutritional supplement (antiobesity agent, anticonstipation agent) of the present invention.
[0036]
In this survey, a questionnaire was prepared and the symptoms before taking the test agent were filled in, and 90 days after the start of taking the test B, the changes in each symptom were rewritten. . Here, when each symptom became very good, it was regarded as "significant effect", when it became better, "effective", when it did not change, it was "ineffective", and when it became worse, it was "deteriorated".
[0037]
Furthermore, regarding the improvement of obesity, the body weight was measured before and after administration of the test agent, and the change was determined based on the change. That is, taking into account measurement errors, a weight loss of 4% or more is regarded as “effective”, a decrease of less than 4% to an increase of less than 4% is “invalid”, and an increase of 4% abnormality is regarded as “deterioration”. . The figures after the decimal point are rounded off.
[0038]
Clinical test results Fig. 1 is a table showing the effect of test agent A on improving constipation, and Fig. 2 is a table showing the effect of test agent B on improving constipation. From these tables, it can be seen that Test Agent B has the same constipation improving effect as Test Agent A. Here, the test subject B was administered for 5 days so that all the subjects did not feel the bloating of the lower abdomen. In addition, the pH value of the stool after administration of test agent B for 5 days is closer to neutral as compared to the pH value after administration of test agent A for 5 days.
[0039]
FIG. 3 is a table showing the overall results of the clinical test. That is, the effect of improving constipation is observed in the same manner in both Test Agents A and B, and Test Agent B has an effect of further preventing the lower abdomen from becoming full. That is, it was found that Test Agent B was an ideal anti-constipation agent.
[0040]
FIG. 4 is a table showing the results of improvement of each complaint when Test Agent B was used for 90 days. As shown in FIG. 4, remarkable improvement results were observed for each complaint. That is, as well as constipation, a high rate of improvement of 90 to 100% was found for irregular menstruation, menstrual pain, back pain, and swelling.
[0041]
FIG. 5 is a table showing changes in body weight of each subject when the test agent B is used continuously for 90 days. As shown in FIG. 5, most of the subjects except for one case showed a remarkable weight loss. In some, taking 9 days of test agent B reduced body weight by 6-9 kg.
[0042]
The dosage of each crude drug per day is an extract equivalent to 1 to 3 g of white peach blossoms, an extract equivalent to 0.5 to 3 g of skin, and an extract equivalent to 1 to 6 g of daisies (Rhodes japonicus) in terms of raw materials. Is considered an appropriate amount. The cinnamon extract can be replaced with a citrus extract or a mixture of a cinnamon extract and a citrus extract.
[0043]
In addition, in the case of administering a mixture of white peach blossom extract and citrus extract (kiko husk) extract, or a combination of cinnamon extract and citrus (kiko husk) extract (the first invention of the present application), 1 g to 3 g of white peach blossom in terms of raw material per day is used. It is considered that an extract corresponding to (i), kikomi (kikomi), or an extract corresponding to 0.5 g to 3 g of a mixture of cinnamon and kikomi is suitable.
[0044]
White peach blossom extract, cinnamon extract, citrus extract, and yotei extract are used by the usual hot water extraction method.
[0045]
【The invention's effect】
As described above, according to the present invention, the addition of daisies to the mixture of the white peach flower extract and the cinnamon and / or citrus (citrus) extract further suppresses the vigorous scavenging effect of the white peach flower, and It is possible to provide a dietary supplement, an anti-obesity agent, or an anti-constipation agent that effectively utilizes the anti-obesity effect of the peach flower due to the metabolism enhancing action and the blood flow improving action, and further suppresses the bloating of the lower abdomen.
[Brief description of the drawings]
FIG. 1 is a table showing the usefulness of a mixture of a conventional white peach extract and a skin extract.
FIG. 2 is a table showing the usefulness of an anti-constipation agent according to the present invention, which is obtained by adding yogurt to the mixture of the white peach extract and the skin extract.
FIG. 3 is a table showing the usefulness of a dietary supplement of the present invention obtained by further adding yogurt to a mixture of a white peach extract and a skin extract.
FIG. 4 is a table showing the usefulness of a dietary supplement comprising a mixture of the white peach flower extract and the cinnamon extract of the present invention to which ginseng is added, against gynecological complaints.
FIG. 5 is a table showing the anti-obesity effect of a dietary supplement comprising a mixture of white peach extract and cinnamon extract according to the present invention, further supplemented with daisies.

Claims (9)

白桃花エキスと枳実エキスとを3:1〜2:5の割合、より好ましくは2:1〜1:2の割合で含むことを特徴とする栄養補助食品。A dietary supplement comprising white peach extract and citrus extract in a ratio of 3: 1 to 2: 5, more preferably 2: 1 to 1: 2. 白桃花エキスと枳実エキスとを3:1〜2:5の割合、より好ましくは2:1〜1:2の割合で含むことを特徴とする抗肥満剤。An anti-obesity agent comprising white peach extract and citrus extract in a ratio of 3: 1-1: 2, more preferably in a ratio of 2: 1-1: 2. 白桃花エキスと、枳実エキスとを3:1〜2:5の割合、より好ましくは2:1〜1:2の割合で含むことを特徴とする抗便秘剤。An anti-constipation agent comprising white peach extract and citrus extract in a ratio of 3: 1-2: 5, more preferably in a ratio of 2: 1-1: 2. 白桃花エキスと;枳実エキスと陳皮エキスの混合物を3:1〜2:5の割合、より好ましくは2:1〜1:2の割合で含むことを特徴とする栄養補助食品。A dietary supplement characterized by comprising a mixture of white peach extract and kikomi extract and cinnamon extract in a ratio of 3: 1 to 2: 5, more preferably 2: 1 to 1: 2. 白桃花エキスと;枳実エキスと陳皮エキスの混合物を3:1〜2:5の割合、より好ましくは2:1〜1:2の割合で含むことを特徴とする抗肥満剤。An anti-obesity agent comprising a mixture of a white peach extract and a citrus extract and a skin extract in a ratio of 3: 1-2: 5, more preferably in a ratio of 2: 1-1: 2. 白桃花エキスと;枳実エキスと陳皮エキスの混合物を3:1〜2:5の割合、より好ましくは2:1〜1:2の割合で含むことを特徴とする抗便秘剤。An anti-constipation agent comprising a mixture of a white peach extract and a citrus extract and a skin extract in a ratio of 3: 1 to 2: 5, more preferably 2: 1 to 1: 2. 白桃花エキスと;陳皮エキスおよび/または枳実エキスと;羊蹄(ギシギシ)エキスとを2:1:2〜1:1:2の割合で含むことを特徴とする栄養補助食品。A dietary supplement comprising: white peach extract; Chen skin extract and / or citrus extract; 白桃花エキスと;陳皮エキスおよび/または枳実エキスと;羊蹄(ギシギシ)エキスとを2:1:2〜1:1:2の割合で含むことを特徴とする抗肥満剤。An anti-obesity agent comprising: a white peach extract; a skin extract and / or a citrus extract; 白桃花エキスと;陳皮エキスおよび/または枳実エキスと;羊蹄(ギシギシ)エキスとを2:1:2〜1:1:2の割合で含むことを特徴とする抗便秘剤。An anti-constipation agent comprising: a white peach flower extract; a rind extract and / or a citrus extract;
JP2003037382A 2003-02-14 2003-02-14 Dietary supplement Pending JP2004244389A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003037382A JP2004244389A (en) 2003-02-14 2003-02-14 Dietary supplement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003037382A JP2004244389A (en) 2003-02-14 2003-02-14 Dietary supplement

Publications (1)

Publication Number Publication Date
JP2004244389A true JP2004244389A (en) 2004-09-02

Family

ID=33022216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003037382A Pending JP2004244389A (en) 2003-02-14 2003-02-14 Dietary supplement

Country Status (1)

Country Link
JP (1) JP2004244389A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006056845A (en) * 2004-08-23 2006-03-02 Teikoku Seiyaku Co Ltd Plaster agent containing extract of plant of rose family
JP2007045771A (en) * 2005-08-11 2007-02-22 Pola Chem Ind Inc Composition for oral administration
JP2007055942A (en) * 2005-08-25 2007-03-08 Pola Chem Ind Inc Composition for oral administration
JP2007204434A (en) * 2006-02-02 2007-08-16 Pola Chem Ind Inc Coffee oil quina acid derivative and composition including the same as an active ingredient for suppressing plasminogen activator inhibitor
JP2021028344A (en) * 2020-11-27 2021-02-25 株式会社東洋新薬 Medicine for intestinal disorders, antiallergic agent, immunoadjuvant, and agent for improving enteroadherent properties of lactic acid bacteria

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006056845A (en) * 2004-08-23 2006-03-02 Teikoku Seiyaku Co Ltd Plaster agent containing extract of plant of rose family
JP2007045771A (en) * 2005-08-11 2007-02-22 Pola Chem Ind Inc Composition for oral administration
JP2007055942A (en) * 2005-08-25 2007-03-08 Pola Chem Ind Inc Composition for oral administration
JP2007204434A (en) * 2006-02-02 2007-08-16 Pola Chem Ind Inc Coffee oil quina acid derivative and composition including the same as an active ingredient for suppressing plasminogen activator inhibitor
JP2021028344A (en) * 2020-11-27 2021-02-25 株式会社東洋新薬 Medicine for intestinal disorders, antiallergic agent, immunoadjuvant, and agent for improving enteroadherent properties of lactic acid bacteria
JP7054552B2 (en) 2020-11-27 2022-04-14 株式会社東洋新薬 Intestinal regulator, anti-allergic agent, immunopotentiator, lactic acid bacterium intestinal adhesion improver

Similar Documents

Publication Publication Date Title
CN102836379B (en) Traditional Chinese medicine compound preparation for reducing lipid and dispelling effects of alcohol as well as preparation method and application of same
CN110447902B (en) Composition with weight-losing effect
WO2011060585A1 (en) Chewable tablets including essences of five-colour fruits and vegetables and preparative methods thereof
CN103263012B (en) Edible and pharmaceutical health-care foodstuff and preparation method thereof
CN100556439C (en) A kind of Chinese medicine composition of orally taken for curing halitosis
KR101632794B1 (en) METHOD OF MANUFACTURING PILL COMPRISED OF Protaetia brevitarsis seulensis
CN104958646A (en) Chinese medicinal preparation for relaxing bowels and preparation method thereof
KR20130063074A (en) Blood glucose and blood pressure decrease action composition
CN107441409A (en) Chinese medicine composition for treating habitual constipation and preparation method thereof
CN107050351B (en) Traditional Chinese medicine composition for relaxing bowel and preparation method and application thereof
JP2004244389A (en) Dietary supplement
KR20080012457A (en) Composition for treating obesity and constipation
CN103416536A (en) Selenium-rich intestine moistening tea and production method thereof
CN100509041C (en) Stomach-clearing pill
WO2008096171A2 (en) Natural laxative composition comprising prunes, raisins, apricots, dates, figs, olive oil, senna and honey
WO2006106888A1 (en) Oral composition for promoting defecation containing patchouli oil and dietary fiber
CN106266687A (en) A kind of health product for treating hypertension and chronic constipation
CN103006980A (en) Chinese medicinal composition for treating distention and fullness
JP7219907B2 (en) Composition for improving lower urinary tract symptoms
CN111068027B (en) Traditional Chinese medicine composition for regulating and treating yang deficiency and sub-health, and preparation method and application thereof
KR20180056199A (en) Manufacturing method of gum for diet containing Moringa Oleifera extract
CN105641521A (en) Orally-taken powder with intestinal canal cleaning function
JP2994594B2 (en) Health food for constipation
KR20040024008A (en) Health food composition for improving constipation
CN105147944B (en) A kind of Chinese medicine composition, its preparation and its preparation method and application

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090714

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091110